The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...

1FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review - Valneva2Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate - Valneva3 This ...

If approved, Valneva’s shot could be the first approved for chikungunya, a virus transmitted by mosquitoes with similar symptoms to dengue and Zika, including severe joint pain that can last years.

18 Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet - Valneva 19 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...